Country Club Bank Sells 114,960 Shares of Elanco Animal Health Incorporated $ELAN

Country Club Bank decreased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 41.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 165,756 shares of the company’s stock after selling 114,960 shares during the period. Country Club Bank’s holdings in Elanco Animal Health were worth $2,369,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Yousif Capital Management LLC bought a new position in shares of Elanco Animal Health in the 1st quarter valued at about $119,000. Wealth Enhancement Advisory Services LLC bought a new position in Elanco Animal Health during the first quarter worth about $111,000. Comerica Bank grew its holdings in Elanco Animal Health by 46.4% during the first quarter. Comerica Bank now owns 49,680 shares of the company’s stock worth $522,000 after purchasing an additional 15,754 shares during the period. SG Americas Securities LLC bought a new position in Elanco Animal Health during the first quarter worth about $891,000. Finally, GAMMA Investing LLC grew its holdings in Elanco Animal Health by 1,743.8% during the first quarter. GAMMA Investing LLC now owns 12,390 shares of the company’s stock worth $130,000 after purchasing an additional 11,718 shares during the period. Institutional investors own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ELAN. JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $18.00 to $24.00 in a report on Tuesday. Stifel Nicolaus lifted their price target on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Elanco Animal Health in a report on Saturday, September 27th. Zacks Research upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 3rd. Finally, William Blair upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research report on Thursday, June 26th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average price target of $19.14.

Elanco Animal Health Stock Down 0.8%

NYSE ELAN opened at $20.49 on Wednesday. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $21.76. The company has a 50 day moving average of $17.98 and a 200-day moving average of $14.23. The company has a market cap of $10.18 billion, a price-to-earnings ratio of 23.82, a PEG ratio of 3.81 and a beta of 1.65.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the previous year, the business earned $0.30 earnings per share. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.